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S U M M A R Y
Background: The capacity of toll-like receptor (TLR) 7/8 agonist-conjugated hepatitis B virus (HBV)
proteins (HBV-Ag) to overcome established hepatitis B surface antigen (HBsAg)-speciﬁc immune
tolerance was explored.
Methods: A TLR7/8 agonist, CL097, was conjugated with alum-absorbed HBsAg and hepatitis B core
antigen (HBcAg), as conﬁrmed by ultra performance liquid chromatography quadrupole time-of-ﬂight
mass spectrometry (UPLC-Q/TOF MS). Mice from two independently generated HBV-transgenic
(HBV-Tg) colonies, C57BL/6J-TgN (AlblHBV) 44Bri/J mice and C57BL/6-HBV-1.3 genome-eq mice, were
immunized with CL097-conjugated HBV-Ag every 2 weeks, four times.
Results: After immunization, 8/11 (72.7%) of the AlblHBV mice and 10/13 (76.9%) of the HBV-1.3
genome-eq mice generated serum detectable antibodies against HBsAg (anti-HBs). HBsAg-speciﬁc
interferon gamma (IFN-g)-producing CD4+ and CD8+ T-cells were detected in splenocytes from these
mice. Naı¨ve normal mice receiving splenocytes from the mice immunized with CL097-conjugated HBV-
Ag generated immediate recall immune responses, e.g., the mice that received CD4+CD25+-depleted
splenocytes generated anti-HBs on day 3 after HBsAg challenge while those receiving cells from sham-
immunized mice did not.
Conclusions: Immunization with CL097-conjugated HBV-Ag reversed immune tolerance in HBV-Tg mice
and induced antigen-speciﬁc immune responses. TLR7/8 agonists appear to be potent adjuvants for the
induction of antigen-speciﬁc Th1 responses in an immune tolerant state.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Adjuvants are crucial for the generation of an optimal immune
response to puriﬁed protein vaccines. Recent advances in our
understanding of innate immunity have led to the identiﬁcation of
immune pathways and adjuvant formulations more suitable for
clinical advancement. One area of particular interest is the discovery
of agonists that target the toll-like receptors (TLRs). Signaling from
the TLRs expressed on monocytes and monocyte-derived dendritic
cells (moDCs), through recognition of various pathogen-associated
molecular patterns, induces these cells to secrete distinct cytokines,* Corresponding author. Tel.: +86 10 8778 3103; fax: +86 10 6771 3917.
E-mail address: quchf@cicams.ac.cn (C. Qu).
http://dx.doi.org/10.1016/j.ijid.2014.07.015
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).which in turn inﬂuence T-cell differentiation.1 Recent research
has demonstrated that microbial stimulation promotes monocyte
differentiation into DC-SIGN/CD209+ moDCs in vivo and these
moDCs exhibit a greater capacity than lymphoid resident dendritic
cells (DCs) to stimulate T-cell proliferation once they acquire the
antigens together with TLR4 ligands.2 Cervarix, a prophylactic
vaccine against human papillomavirus (HPV) types 16 and 18,
recently received approval from the US Food and Drug Administra-
tion (FDA).3 In this vaccine, viral antigens are formulated with
monophosphoryl lipid A, a TLR4-targeted adjuvant, which confers
protective immunity against HPV and promotes immune response
broadening. Other adjuvants targeting TLRs are in development for
new therapeutic vaccine candidates for cancers and some chronic
infectious diseases.3,4ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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virus (HBV) infection is supported by ﬁndings that bone marrow
transplantation of anti-HBV immunity to the recipient could cure
chronic HBV infection.5,6 A therapeutic vaccine, which represents
one of the immunotherapy strategies, has been developed in
different forms.7–10 However, the clinical response to these
vaccines has been poor, probably because of immune tolerance
to HBV viral antigens.11,12 Patients who recover from acute HBV
infections usually have vigorous antibody responses, with anti-
bodies against hepatitis B surface antigen (anti-HBs) easily
detectable, and polyclonal T-cell responses against multiple HBV
antigens (HBV-Ag).13,14 Therefore, it is important for an effective
therapeutic vaccine to induce multiple HBV antigen-speciﬁc
responses by activating both antigen-speciﬁc CD4+ and CD8+
T-cells in the immune tolerant state.
Previously, we reported that human monocytes differentiated
into moDCs when they phagocytosed dead cells containing ssRNA,
the TLR7/8 agonist, and induced strong CD8+ T-cell responses to
the cell-associated antigens.15 Using chemically synthesized TLR7/
8 agonists we demonstrated that CL075 and CL097 stimulated
newly recruited monocyte-derived cells into potent antigen-
presenting cells (APCs) that enhance hepatitis B surface antigen
(HBsAg) immunogenicity in both humans and mice.16 TLR7/8
agonists conjugated to HIV Gag protein have been shown to
enhance the magnitude and quality of Th1 and CD8+ T-cell
responses in non-human primates.17,18 TLR7/8 agonists appear to
be good candidate adjuvants for prophylactic vaccines to induce
Th1 responses in normal animals.16–20 However, it is unknown
whether TLR7/8 agonist-conjugated vaccines could break the
established antigen-speciﬁc tolerance and induce antigen-speciﬁc
immune responses.
2. Materials and methods
2.1. Mice and reagents
C57BL/6 male wild-type mice and two independently generat-
ed HBV transgenic (HBV-Tg) mouse colonies (males, 7–8 weeks)
with C57BL/6 background were used. C57BL/6-HBV-1.3 genome-
eq transgenic mice were generated in the Transgenic Laboratory,
Infectious Disease Center, Guangzhou.21 HBsAg-transgenic C57BL/
6J-TgN (AlblHBV) 44Bri/J mice, which were originally generated in
the laboratory of Dr Chisari, were purchased from Peking
University, China. Both colonies constitutively express HBsAg in
liver cells and secrete HBsAg in serum, as reported previously.22 All
procedures involving mice were approved by the Institutional
Animal Care and Use Committee of the Cancer Institute, Chinese
Academy of Medical Sciences.
Recombinant HBsAg (yeast) was from Dalian Hissen Bio-pharm
Inc.; recombinant inﬂuenza A H1N1 virus M1 protein (Escherichia
coli) was from QuantoBio Biotechnology. Endotoxin levels of these
proteins were less than 1.0 EU/mg protein. Recombinant hepatitis B
core antigen (HBcAg) (E. coli) was from Jianan Biotechnology, China
(endotoxin level 0.14 EU/mg protein). ELISA kits for quantifying
HBsAg and anti-HBs were purchased from Wantai Biological
Pharmacy, China. The TLR7/8 agonist, CL097, was purchased from
InvivoGen (CA, USA); aluminum hydroxide gel was from Sigma-
Aldrich (MO, USA). All chemicals for ultra performance liquid
chromatography (UPLC) were analytical grade.
Detailed information on the materials and methods are
provided in the Supplementary Material.
2.2. Preparation of vaccines and immunization protocol
To prepare the TLR7/8 agonist-conjugated vaccine, HBsAg and
HBcAg (5 mg of each) were diluted in 50 ml normal saline andmixed with the same volume of aluminum hydroxide (500 mg) at
room temperature; 5 mg CL097 was then added. For immunization,
each mouse received 5 mg HBV-Ag every 2 weeks.
2.3. Conﬁrmation of CL097 conjugation with alum-absorbed HBV-Ag
by UPLC-Q/TOF MS
UPLC quadrupole time-of-ﬂight mass spectrometry (UPLC-Q/
TOF MS) was performed using an Acquity UPLC BEH C18 column on
the Acquity UPLC system, equipped with SYNAPT G2 HDMS
(Waters Corp., UK) with an electrospray ionization source (ESI) in
positive ion mode. The column was maintained at 40 8C and eluted
at a ﬂow rate of 0.45 ml/min, using a mobile phase of 0.1% formic
acid in water (18.2 mV) and acetonitrile (HPLC grade; J.T. Baker,
Phillipsburg, NJ, USA). Leucine-enkephalin was used as the lock
mass in all analyses (m/z 556.2771) at 0.5 mg/ml, with a ﬂow rate
of 5 ml/min. Data were collected in centroid mode from m/z 100 to
m/z 1500.
A series of standard working solutions was prepared and 5 ml of
each was injected into the UPLC system for analysis after
centrifugation at 6500 g for 5 min. CL097-conjugated HBV-Ag
solution was divided into two parts after the same centrifugation.
The pellet was resuspended in 20% sodium citrate solution and
incubated at 37 8C for 2 h followed by the same centrifugation. All
the supernatant was analyzed by UPLC-Q/TOF MS.
2.4. Flow cytometry analysis (FACS; ﬂuorescence activated cell sorting)
Fluorescence-conjugated antibodies to mouse CD3, CD4, CD8,
interferon gamma (IFN-g), CD25, and FoxP3 were purchased from
eBioscience (CA, USA). Flow cytometry staining for cell surface
markers or intracellular cytokines was done using standard
laboratory protocols. Data were acquired in an LSR-II (Becton-
Dickinson, San Diego, CA) and analyzed using Flowjo software
(Tree Star Inc, Asland, OR).
2.5. Assays for HBsAg-speciﬁc antibody-secreting cells (ASCs)
The presence of HBsAg-speciﬁc ASCs in immunized mouse
splenocytes was determined by ELISPOT assay, as described in the
literature.23 Further details of the materials and methods are
provided in the Supplementary Material.
2.6. Assays for HBsAg-speciﬁc T-cell cytokine production
Splenocytes were isolated from immunized normal or HBV-Tg
mice and cultured in the presence of 5 mg HBsAg for 72 h, followed
by the addition of 1 Brefeldin A Solution (Becton-Dickinson, San
Diego, CA) for another 6 h. Cells were collected and stained using
standard FACS staining protocols.
2.7. Cell sorting and transfer
Single splenocytes of HBV-1.3 genome-eq transgenic mice that
were untreated or immunized with CL097-conjugated HBV-Ag,
were labeled with ﬂuorescein isothiocyanate (FITC)-conjugated
CD4 and PE-Cy5-conjugated CD25 antibodies. The cells were
sorted into two parts: CD4+CD25+ (Treg cells) and CD4+CD25+-
depleted populations (non-Treg) using a FACSAria (BD, USA).
Because Treg is only about 10% of peripheral CD4+ T-cells,24 each
naı¨ve C57BL/6J mouse received 2  105 Treg or 2  106 non-Treg
cells from sham-treated or immunized mice (in 200 ml phosphate
buffered saline) via the tail vein.25 On the following day, all
recipient mice were challenged intramuscularly with 5 mg
recombinant HBsAg or 5 mg recombinant inﬂuenza A H1N1 M1
proteins. Serum samples were collected on days 3, 6, 9, and
Figure 1. Effect of TLR7/8 agonist on speciﬁc immune responses against HBsAg in wild-type C57BL/6 mice. (A) Structure of CL097 and its ESI mass spectrum (m/z 243!197) in
positive ion mode performed in UPLC-Q/TOF MS. (B) Relative peak intensity of CL097 bound with alum. (C) Serum levels of anti-HBs measured 2 weeks after the second
immunization (ﬁve mice per group, each was repeated three times). G1: immunization with 5 mg HBV-Ag absorbed to alum; G2: immunization with 5 mg HBV-Ag and 5 mg
CL097 absorbed to alum; G3: immunization as for G1 in one side of the mice, 5 mg CL097 solution was injected in the other side; G4: immunization with 5 mg HBV-Ag and
5 mg CL097 without absorbing to alum. No anti-HBs was detectable in the naı¨vemice or the mice immunized with aluminum hydroxide alone (Alum) or CL097 alone (CL097);
*p < 0.05, **p < 0.01 determined by all-pairs Tukey–Kramer analysis. (D) Frequency of HBsAg-speciﬁc, HBcAg-speciﬁc CD4+ and CD8+ IFN-g-producing T-cells in the group
pooled splenocytes based on FACS staining (Supplementary Material, Figure S1) (ﬁve mice per group, each was repeated three times); *p < 0.05, **p < 0.01 determined by
two-tailed Student’s t-test.
Y. Wang et al. / International Journal of Infectious Diseases 29 (2014) 31–36 3312. Anti-HBs serum levels were quantiﬁed using a commercialized
ELISA kit; anti-M1 levels were determined using a direct ELISA
assay developed in our laboratory.
2.8. Statistical analysis
The statistical analysis was conducted using SPSS software
(11.0). Statistical tests were performed using all-pairs Tukey–
Kramer analysis and/or the two-tailed Student’s t-test.
3. Results
3.1. Binding of TLR7/8 agonist with particulate antigens is necessary
to induce optimal humoral and cellular immune responses against
HBsAg
Under physiological conditions (pH 7.2–7.4), alum hydroxide
adjuvants have a positive surface charge, while CL097, HBsAg, and
HBcAg have a negative surface charge. Theoretically, CL097 binds
to alum via the surface charge using the bond present in the N atomTable 1
Binding of CL097 and HBV antigens with different amounts of aluminum hydroxide
Aluminum
hydroxide (mg)
Added CL097 (5 mg) 
Normal saline 20% sodium citrate
Bound Free Bound 
0 0 4.98 0 
200 4.23 0.75 2.56 
500 4.95 0.03 2.05 
750 4.73 0.25 2.04 
1000 4.93 0.05 2.78 
HBV, hepatitis B virus.(Figure 1A). Using UPLC-Q/TOF MS, we conﬁrmed the conjugation
of CL097 to alum (Figure 1B). The conjugation was stable at normal
pH but was partially dissociated when sodium citrate solution was
added (Table 1). Conjugation of HBV-Ag, the HBsAg and HBcAg
proteins, with alum was conﬁrmed using the bicinchonnic acid
(BCA) assay (Table 1).
In comparison to the immunized mice with alum absorbed
HBV-Ag (G1 in Figure 1C), the serum level of anti-HBs in the
immunized mice using CL097-conjugated HBV-Ag through alum
was signiﬁcantly increased (G2, in Figure 1C). The antibodies
against HBcAg in the two groups of mice showed a similar pattern
(data not shown). However, no similar effect on antibody
production was observed when CL097 was injected in free form,
without being absorbed with HBV-Ag through alum (G3 in
Figure 1C), or mixed with HBV-Ag without alum (G4 in
Figure 1C). The percentage of HBsAg-speciﬁc, HBcAg-speciﬁc
IFN-g-producing T-cells was also signiﬁcantly increased in the
mice immunized with CL097-conjugated HBV-Ag (with CL097, in
Figure 1D; Supplementary Material, Figure S1) compared to theAdded HBV antigens (10 mg)
 Normal solution 20% sodium citrate
Free Bound Free Bound Free
4.98 0 10.8 0 10
2.42 8.8 0 0 8.8
2.93 10 0 0 10
2.94 10.1 0 0 10
2.2 10.2 0 0 10.2
Figure 2. Humoral immune responses to HBsAg in HBV-Tg mice immunized with CL097-conjugated HBV-Ag. (A, B) Serum anti-HBs levels measured at 2 weeks after four-dose
immunization with CL097-conjugated HBV-Ag (HBV-Ag) in Alb1HBV 44Bri/J mice (A, n = 11) and in HBV-1.3 genome-eq mice (B, n = 13). Alum absorbed CL097 was used as
the sham-immunization (sham). Each dot represents one mouse. (C) Spearman’s correlation analysis between serum anti-HBs levels and the pre-immunized serum
concentration of HBsAg in individual HBV-1.3 genome-eq mice. (D) Serum concentration of anti-HBs measured 20 weeks after the fourth immunization (Pre-Bst) and 2 weeks
after one dose of booster (Af-Bst) using CL097-conjugated HBV-Ag (n = 5); **p < 0.01 determined by two-tailed Student’s t-test. (E) Serum ALT levels measured at different
time points before (pre-immu) and after the immunization. Each dot represents one mouse.
Y. Wang et al. / International Journal of Infectious Diseases 29 (2014) 31–3634mice immunized with HBV-Ag alone (without CL097, in Figure 1D;
Supplementary Material, Figure S1).
3.2. Immunization with CL097-conjugated HBV-Ag results in the
generation of anti-HBs antibodies and HBsAg-speciﬁc T-cells in
HBV-Tg mice
The effects of TLR7/8 agonist-conjugated HBV-Ag were then
examined in HBV-Tg mice. To conﬁrm the results, we tested it in
two independently prepared HBV-Tg mouse colonies. In the
AlblHBV 44Bri/J mice, a total of 8/11 (72.7%) generated serum
anti-HBs antibodies following immunization with four doses
of CL097-conjugated HBV-Ag, averaging 636  258 mIU/ml
(Figure 2A). In the C57BL/6-HBV-1.3 genome-eq mice, a total of
10/13 (76.9%) of the mice had serum detectable anti-HBs antibodies,
with an average of 425  118 mIU/ml (Figure 2B).
The effect of the serum HBsAg concentration on anti-HBs
production was analyzed in the C57BL/6-HBV-1.3 genome-eq
mice. Generally, no correlation was found between serum anti-HBs
levels and the corresponding pre-immunized serum HBsAg
concentration in each mouse (R2 = 0.077, p = 0.357) (Figure 2C).Figure 3. HBsAg-speciﬁc B-cells and T-cells in immunized HBV-Tg mice. (A) The numbers
2 weeks after boosting with CL097-conjugated HBV-Ag (CL097). Samples from the mice
coated with HBsAg were used as spontaneous release controls (Med); *p < 0.05 determi
each sample well. Each spot (black arrows) represents one HBsAg-speciﬁc B-cell. (C) Sple
the mice immunized with alum absorbed CL097 alone (Sham) were re-stimulated with
cytokine staining (representative of ﬁve independent experiments).However, anti-HBs was detectable in all mice with less than
3 mg/ml serum HBsAg (Figure 2C).
Anti-HBs persisted for more than 20 weeks after antibodies
were initially induced. Following a single dose of vaccine booster,
the concentration of anti-HBs increased dramatically (Figure 2D).
Mice treated with alum-conjugated CL097 alone (sham-immuni-
zation) had no detectable serum anti-HBs (Figure 2, A and B).
Serum alanine aminotransferase (ALT) levels were elevated in
some vaccine-immunized and some sham-immunized HBV-Tg
mice. On weeks 10 and 20, serum ALT returned to the same levels
as untreated HBV-Tg mice (Figure 2E).
Representative mice that had anti-HBs generated were eutha-
nized at week 22 after the vaccine booster. Splenocytes from the
mice immunized with CL097-conjugated HBV-Ag contained more
HBsAg-speciﬁc B-cells than those from sham-immunized mice
(Figure 3, A and B). After the splenocytes were stimulated with
HBsAg in vitro, IFN-g-producing CD4+ and CD8+ T-cells were
also detected in immunized HBV-Tg mice with a more obvious
increase in the number of IFN-g-producing HBsAg-speciﬁc CD8+
T-cells compared to the sham-immunized mice (Figure 3C).
These results indicate that inclusion of TLR7/8 agonist CL097 in of HBsAg-speciﬁc antibody secreting cells (ASC) were determined by ELISPOT assay
 immunized with alum absorbed CL097 alone (sham) were also assayed. Wells not
ned by two-tailed Student’s t-test. (B) Images showing representative ASC spots in
nocytes isolated from mice immunized with CL097-conjugated HBV-Ag (HBV-Ag) or
 HBsAg. HBsAg-speciﬁc IFN-g-producing T-cells were determined by intracellular
Figure 4. Frequency and function of Treg cells in the mice immunized with CL097-conjugated HBV-Ag. (A) Frequency of CD3+CD4+CD25+FoxP3+ Treg cells in splenocytes of
the sham-immunized (sham) or the mice immunized with CL097-conjugated HBV-Ag (CL097) (representative of three independent experiments). (B) Sorting strategy of
CD4+CD25+ Treg (G1) and CD4+CD25+-depleted (G2) cell populations. Each of the sorted cell populations, 2  105 cells/mouse for CD4+CD25+ and 2  106 cells/mouse for
CD4+CD25+-depleted cells, were injected intravenously into naı¨ve C57BL/6 mice (n = 3). Dot plot indicating the splenocytes from mice immunized with CL097-conjugated
HBV-Ag. On the day of cell transfer, each mouse received 5 mg HBsAg or 5 mg inﬂuenza A virus M1 protein intramuscularly. (C) Anti-HBs in mice that received the G1 or G2
cells, as indicated in Figure 4B, from sham-immunized mice was undetectable (dashed line). Serum anti-HBs levels in mice that received cells from CL097-conjugated HBV-Ag
immunized mice are shown as solid lines. (D) Serum levels of antibodies against inﬂuenza A virus M1 proteins in the same mice on day 12.
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response against tolerant HBsAg antigens in HBV-Tg mice.
3.3. Immunization with CL097-conjugated HBV-Ag breaks
antigen-speciﬁc immune tolerance in HBV-Tg mice
CD4+CD25+ Treg cells play an important role in maintaining
immune tolerance. The percentage of CD4+CD25+FoxP3+ Treg
cells decreased signiﬁcantly in the vaccine-immunized (2.6%)
versus sham-immunized mice (6.72%) (Figure 4A). We then sorted
splenocytes from the immunized mice into two populations –
CD4+CD25+ and CD4+CD25+-depleted cells – and transferred each
of them intravenously into naı¨ve C57BL/6J mice, followed by
challenge with HBsAg or non-relevant inﬂuenza A virus M1 protein
(depicted in Figure 4B). The mice that received CD4+CD25+-
depleted splenocytes from immunized mice generated anti-HBs
immediately after HBsAg challenge, while those receiving cells
from sham-immunized mice did not. Antibodies were detected as
early as on day 3 and reached a plateau by day 9 (Figure 4C). The
mice that received CD4+CD25+ cells from the vaccine-immunized
mice generated anti-HBs antibodies by day 12 (Figure 4C). Mice
receiving splenocytes from vaccine- or sham-immunized HBV-Tg
exhibited similar responses to non-relevant M1 proteins
(Figure 4D). These results suggest that immune tolerance to
HBsAg was broken and speciﬁc immune responses against HBsAg
were generated in HBV-Tg mice by immunization with CL097-
conjugated HBV-Ag.
4. Discussion
Most chronic HBsAg carriers are infected in early life,26 and viral
persistence has been associated with a defect in the development
of speciﬁc immunity against HBV viral proteins.5,6,27 It is important
for therapeutic vaccines to overcome immune tolerance and
induce both speciﬁc antibodies against HBsAg and T-cell immunity
against HBV structural proteins in the presence of chronic HBV
infection.11,12,27 Our results demonstrated that binding of TLR7/8agonist to alum-absorbed HBV-Ag was able to break the immune
tolerance and induce humoral and cellular immune responses
against HBsAg in HBV-Tg mice.
Many TLR agonists can be potent adjuvant candidates for
improving the magnitude and quality of memory T-cell
responses.4,17,18 However, systemic activation of DCs by TLR
ligands inhibits their antigen presentation function.28 Monocytes
express a variety of TLRs, patrol various tissues for signs of
infection and inﬂammation, and are approximately 20 times more
abundant than DCs in blood and bone marrow. Therefore,
monocytes are a promising target for the design of prophylactic
and therapeutic vaccines against some chronic diseases.2,29 TLR7/8
are mainly expressed in intracellular compartments and sense the
ligands when the cells take up the ligands.30 In this study, we
demonstrated that binding CL097 with HBV-Ag through alum
resulted in better immune responses than did the free form of
CL097. We reported previously that the immunogens were mainly
taken up by monocytes and monocyte-derived cells after
immunization.16 Therefore, TLR7/8 conjugation with immunogens
appeared important for inducing monocyte differentiation into
potent moDCs that could prime naı¨ve T-cells.
TLR expression patterns are different in mice and humans.
Distinct DC subsets also have different TLR expression patterns.1
TLR7 and TLR8 are intracellularly expressed and recognize ssRNA
and synthetic antiviral imidazoquinoline components.1,30 In
humans, TLR7 is mainly expressed in plasmacytoid DCs (pDCs),
which produce high levels of type I IFNs in response to microbial
stimulation. TLR8 is expressed in various tissues, with the highest
levels in myeloid DCs and monocytes.1,31 In mice, TLR8 is non-
functional and TLR7/8 agonists work through TLR7, which is
expressed in murine monocytes and moDCs. The effect in humans
might be different from what we observed in this murine system.
However, stimulation with TLR7/8 agonists in both humans and
mice has been shown to generate Th1-polarizing moDCs.16,20,32
An elevation of serum ALT levels was observed in our vaccine-
immunized mice, which might be harmful for patients with
chronic HBV infection. Clinically, patients exhibit increased serum
Y. Wang et al. / International Journal of Infectious Diseases 29 (2014) 31–3636ALT levels during and after seroconversion from the status of
hepatitis e antigen (HBeAg)-positive to anti-HBe-positive as a
result of the immunological elimination of HBV-expressing liver
cells. Consequently, this translates into reduced viral loads and
clinical remission.33 In this study, HBsAg-speciﬁc B-cells and
IFN-g-producing CD4+ and CD8+ T-cells were only detected in
vaccine-immunized but not in sham-treated HBV-Tg mice. The
elevated serum ALT levels in vaccine-immunized mice were
probably due to the effect of immunological elimination on HBsAg-
expressing liver cells. However, we could not exclude the
possibility of non-speciﬁc damage caused by the TLR7/8 agonists
on liver cells, since the sham-treated mice also exhibited elevated
ALT.
In conclusion, HBV-Ag conjugated with TLR7/8 agonists
reversed the HBsAg-speciﬁc non-responses in HBV-Tg mice.
TLR7/8 agonists appear to be good candidate adjuvants for
therapeutic vaccines to induce Th1 responses in the presence of
a tolerant state, in addition to their reported effects when used in
prophylactic vaccines.16–20
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